Forest earnings drop on higher costs

Forest Laboratories ($FRX) posted a drop in fiscal second-quarter earnings on higher costs, but sales rose 9%, thanks to strong early sales of two new products. But revenue still depends heavily on two older products, Lexapro and Namenda, that are on the verge of losing patent protection, and analysts wonder whether Forest's new drugs are novel enough to capture sizable market share. Report | News

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.